Evidence map›Paper›PMID 37030592›Full record

ArticleThe Journal of allergy and clinical immunology2023

Development of mouse models with restricted HLA-B∗57:01 presentation for the study of flucloxacillin-driven T-cell activation and tolerance in liver injury.

Suryatheja Ananthula, Kirthiram Krishnaveni Sivakumar, Marco Cardone, Shan Su, Gregory Roderiquez, Hanan Abuzeineh, David E Kleiner, Michael A Norcross, Montserrat Puig

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of allergy and clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Genetic and Genomic Approaches to the Study of Drug-Induced Liver Injury.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Review
  4. Review
  5. Review
  6. Immuno-inflammatoryFrontiers in immunology · 2023
    Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Suryatheja AnanthulaLaboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Md.
Kirthiram Krishnaveni SivakumarLaboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Md.
Marco CardoneLaboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Md.
Shan SuLaboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Md.
Gregory RoderiquezLaboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Md.
Hanan AbuzeinehLaboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Md.
David E KleinerLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Md.
Michael A NorcrossLaboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Md.
Montserrat PuigLaboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Md. Electronic address: Montserrat.puig@fda.hhs.gov.
United States Food and Drug Administration · USNational Institutes of Health · US

Funding

Postmortem PathologyZICBC010685 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KLEINER, DAVID ERWIN · 2009 to 2025
$14.3M
Intramural FDA HHS FD999999
6 · The paper itself

Abstract

backgroundFlucloxacillin (FLX)-induced liver injury is immune-mediated and highly associated to HLA-B∗57:01 expression. Host factors leading to drug-induced liver injury are not yet well understood.

objectiveCharacterize in vivo immune mechanisms determining the development of CD8

methodsHLA-B∗57:01 transgenic mice (Tg) or Tg strains with H2-K

resultsCD8

conclusionsIn our in vivo models, FLX primes CD8

Indexed as

CD8-Positive T-LymphocytesChemical and Drug Induced Liver InjuryAnimalsDisease Models, AnimalFloxacillinHistocompatibility Antigens Class IHLA AntigensHLA-B AntigensHumansMiceMice, TransgenicProgrammed Cell Death 1 ReceptorFloxacillinHistocompatibility Antigens Class IHLA AntigensHLA-B57 antigenHLA-B AntigensProgrammed Cell Death 1 Receptordrug-induced liver injuryFlucloxacillinHLA-B∗57:01 transgenic micetolerance

Identifiers

PMID37030592
PMCPMC10524621
OpenAlexW4362658843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.